Medicinal use of marijuana

New England Journal of Medicine

Volumn 368, Issue 9, 2013, Pages 866-868

  Bostwick, J Michael ^a   Reisfield, Gary M ^b   DuPont, Robert L ^c,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Institute for Behavior and Health   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DRONABINOL; NABILONE; NABIXIMOLS; DOXORUBICIN; PLANT MEDICINAL PRODUCT;

ANXIETY; CANNABIS ADDICTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG USE; FATIGUE; HUMAN; LUNG DISEASE; MEDICAL RESEARCH; MOOD; NAUSEA; NOTE; PAIN; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; TREATMENT INDICATION; VOMITING; AGED; ARTICLE; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; MEDICINAL PLANT; METASTASIS; PHYTOTHERAPY; SPINAL CORD TUMOR;

AGED; BREAST NEOPLASMS; CANNABIS; DOXORUBICIN; FATIGUE; FEMALE; HUMANS; NAUSEA; PAIN; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; SPINAL NEOPLASMS;

MLCS; MLOWN;

EID: 84874369320     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde1300970     Document Type: Article

References (13)

1. Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J 2012;6:18-25.
2. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc 2012;87:172-86.
3. Mechoulam R. Cannabis - a valuable drug that deserves better treatment. Mayo Clin Proc 2012;87:107-9.
4. Nussbaum AM, Boyer JA, Kondrad EC. "But my doctor recommended pot": medical marijuana and the physician-patient relationship. J Gen Intern Med 2011;26:1364-7.
5. Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012;83:1-10.
6. Kleber JD, DuPont RL. Physicians and medical marijuana. Am J Psychiatry 2012;169:564-8.
7. McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 1997;3:39-45.
8. Battistella G, Fornari E, Thomas A, et al. Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PLoS One 2013;8(1):e52545.
9. Henstridge CM. Off-target cannabinoid effects mediated by GPR55. Pharmacology 2012;89:179-87.
10. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 2010;126:301-13.
11. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009;23:133-44.
12. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist 2011;16:1203-14.
13. Lown B. The lost art of healing: practicing compassion in medicine. Boston: Houghton Mifflin, 1996.